$ICLK Shares Exceed 52-Week High

iClick Interactive Asia Group Limited (NASDAQ:ICLK) traded today at a new 52-week high of $14.16. Approximately 366,000 shares have changed hands today, as compared to an average 30-day volume of 1.3 million shares.

iClick Interactive Asia Group Ltd is an independent online marketing and enterprise data solutions provider in China. It serves as an integrated cross-channel gateway that provides marketers with innovative and cost-effective ways to optimize their online marketing efforts throughout their marketing cycle and achieve their branding and performance-based marketing goals. It has two operating segments: Marketing Solutions, and Enterprise Solutions. Geographically, it derives majority revenue from PRC and also has a presence in Hong Kong and other countries.

iClick Interactive Asia Group Limited (NASDAQ:ICLK) is currently priced 24.5% above its average consensus analyst price target of $10.14.

Over the past year, iClick Interactive Asia Group Limited has traded in a range of $3.01 to $14.16 and is now at $13.43, 346% above that low.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

$ICLK Enterprise Solutions Deliver Incredible Results for Cosmetic & Beauty Brand KANS

iClick Interactive Asia Group (NASDAQ: ICLK), an independent online marketing and enterprise data solutions provider in China, today reported the successful results from its partnership with KANS, an innovative Chinese cosmetic and beauty brand under Shanghai Chicmax Cosmetics Co., Ltd. (“Chicmax Group”). KANS saw a surge in its online consumer retention rate to 86% and purchase rate to 42.7% within the one-month period that it utilized iClick’s Enterprise Solutions. “Helping prestigious brands like KANS that operate in highly competitive industries achieve remarkable breakthroughs and business expansion is core to iClick’s mission,” iClick CEO and Co-Founder Jian “T.J.” Tang stated in the news release. “We are proud to have helped KANS further expand its online marketing capabilities. With such a strong demonstration of the power of iClick’s solutions, I believe we are well positioned to replicate the success to more companies in China’s booming cosmetics industry. Brands increasingly recognize the value iClick can provide in maximizing customer lifetime value, and we will remain focused on providing even more powerful solutions as we further develop our Integrated Enterprise and Marketing Cloud Platform.”

To view the full press release, visit https://ibn.fm/0XAjq

About iClick Interactive Asia Group Limited

iClick Interactive Asia Group is an independent online marketing and enterprise data solutions provider that connects worldwide marketers with audiences in China. Built on cutting-edge technologies, iClick’s proprietary platform possesses omni-channel marketing capabilities and fulfils various marketing objectives in a data-driven and automated manner, helping both international and domestic marketers reach their target audiences in China. Headquartered in Hong Kong, iClick was established in 2009 and is currently operating in ten locations worldwide, including Asia and Europe. For more information about the company, please visit ir.i-Click.com.

NOTE TO INVESTORS: The latest news and updates relating to ICLK are available in the company’s newsroom at http://ibn.fm/ICLK

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Cybin Inc. (NEO: CYBN) Announces Partnership with Neurotech Pioneer to Leverage Innovative Technology for Psychedelic Therapeutics

$CNPOF Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Court Order for Plan of Arrangement

TORONTO , Jan. 20, 2021 – Canopy Rivers Inc. (” Rivers ” or the ” Company “) (TSX: RIV) (OTC: CNPOF) today filed and mailed the management information circular (the ” Circular “) and related materials in connection with the special meeting (the ” Meeting “) of shareholders to be held virtually on February 16, 2021 at 10:00 a.m. ( Toronto time).

In light of the ongoing coronavirus pandemic and to mitigate against its risks, the Meeting will be held in a virtual only format via live audio webcast, available to all stakeholders at http://web.lumiagm.com/261351529 , password “canopy2021” (case sensitive). During the audio webcast, shareholders will be able to hear the Meeting live, and registered shareholders and duly appointed and registered proxyholders will be able to submit questions and vote while the Meeting is being held.

At the Meeting, shareholders will be asked to consider and, if deemed advisable, to pass a special resolution approving the previously announced plan of arrangement (the ” Transaction “) with Canopy Growth Corporation (” Canopy Growth “) (TSX: WEED, NASDAQ: CGC), pursuant to which Rivers will transfer three portfolio assets to Canopy Growth in exchange for $115 million in cash, 3,750,000 common shares ¹ in Canopy Growth, and the cancellation of all the multiple voting shares (” MVS “) and subordinate voting shares (” SVS “) of Rivers held by Canopy Growth. As part of the Transaction, the Company will also change its corporate name to “RIV Capital Inc.”

In addition, Rivers is pleased to announce that on January 14, 2020 , it was granted an interim order by the Ontario Superior Court of Justice (Commercial List) (the ” Court “) authorizing various matters, including the holding of the Meeting and the mailing of the Circular.

The Company’s board of directors, other than certain conflicted directors (the ” Board “), unanimously approved the Transaction following a unanimous recommendation of a special committee, which was composed of directors independent of Canopy Growth, TerrAscend Corp. (” TerrAscend “) and management of Rivers. Both the special committee and the Board determined that the Transaction is fair to, and in the best interests of, the Company and unanimously recommend that shareholders vote in favour of the Transaction at the Meeting.

Benefits to Rivers Shareholders

Rivers believes the Transaction will propel the Company to its next phase of growth. The Company believes the Transaction will provide the following benefits, among others:

• Enables the Company to access new investment opportunities: Upon completion of the Transaction, the Company will be in a position to comprehensively re-evaluate its business and investment strategy and pursue previously unavailable opportunities, and in particular, investments in, or acquisitions of, opportunities in the U.S. market. As such investments or acquisitions may be inconsistent with the policies of the TSX, the Company is initiating the process to de-list from the TSX and list its securities on a stock exchange that does not prohibit such investments or acquisitions.
• Unlocks value for the Company: The Transaction allows the Company to unlock and realize the value of the TerrAscend exchangeable shares, which have significant liquidity restrictions and the value of which has not been adequately reflected in the Company’s share price, as well as its interest in Les Serres Vert Cannabis Inc., a private company for which there is no published market.
• Provides significant value and liquidity for the Company: The consideration payable by Canopy Growth pursuant to the Transaction is comprised of cash and highly liquid securities, which provides the Company with significant value and liquidity at a price that may not be available in the short to medium term in the absence of the Transaction, particularly in an uncertain economic and market environment. The Company will also have significant capital to pursue potential material investments in, or acquisitions of, established operating businesses in the U.S. cannabis market, many of which continue to experience uncertain and constrained access to capital.
• Eliminates the Company’s dual-class share structure: Upon closing of the Transaction, the Company and its shareholders will derive a number of benefits associated with the elimination of the Company’s dual class share structure, including that:
  • shareholders will have a vote that is proportionate to their relative economic interest in the Company; and
  • the Company’s shares will be more attractive for purposes of raising capital or as an acquisition currency.

Meeting Materials
Shareholders should refer to the Circular and related materials for detailed instructions on how to vote and participate at the Meeting. The Circular also contains important information regarding the Transaction, and a summary of the events leading up to the Transaction, including the reasons that led the Board to determine that the Transaction is fair to Rivers and in the best interest of the Company. The Circular and related materials are available on the Company’s profile at www.sedar.com .

Shareholders can also view the Transaction details in a presentation prepared by the Company, available at www.canopyrivers.com/investors .

Meeting Details
The Transaction requires the approval of at least (a) two-thirds of the votes cast by both: (i) Canopy Growth as the holder of all of the MVS; and (ii) Rivers shareholders that hold SVS, and (b) a simple majority of the votes cast by holders of SVS, excluding the votes attached to the SVS held by Canopy Growth. Canopy Growth has agreed to vote all of its MVS and SVS in favour of the Transaction.

Funds managed by JW Asset Management, the Company’s largest holder of SVS, and each of the Company’s directors and executive officers, which in aggregate represent approximately 24.5% of the outstanding SVS, excluding the SVS held by Canopy Growth, have entered into voting support agreements agreeing to vote their SVS in favour of the Transaction.

Shareholders who are unable to virtually attend the Meeting are encouraged to complete, sign, date and return the form of proxy or voting instruction form provided with the meeting materials so that as many shareholders as possible are represented at the Meeting.

For any questions or assistance with voting their proxies, shareholders should contact Kingsdale Advisors, the strategic shareholder advisor and proxy solicitation agent, by telephone at 1-800-749-9052 (416-867-2272 for collect calls outside of North America ) or by email at contactus@kingsdaleadvisors.com .

About Canopy Rivers
Canopy Rivers is a venture capital firm specializing in cannabis with a portfolio of 17 companies across various segments of the cannabis value chain. We believe that bringing together people, capital, and ideas raises the potential of the entire cannabis industry. By leveraging our industry insights, in-house expertise, and thesis-driven approach to investing, we aim to provide shareholders with exposure to specialized and disruptive cannabis companies. Our mission is to invest in innovators across the cannabis value chain, help them grow, and ultimately create value by guiding these companies towards a monetization event. Together with our portfolio, we are helping build the cannabis industry of tomorrow, today.

Forward Looking Statements
This news release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of Canopy Rivers with respect to future business activities and operating performance. To the extent any forward-looking information in this news release constitutes “financial outlooks” within the meaning of applicable Canadian securities laws, the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such financial outlooks. Forward-looking information is often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions, and forward-looking information in this news release includes, but is not limited to, information and statements regarding: whether and when the Transaction will be consummated; the anticipated benefits of the Transaction, the Company’s expectation that the Transaction will significantly strengthen the Company’s capital and liquidity position, the anticipated cash proceeds from the Transaction net of the associated tax liability and transaction costs, the anticipated benefits associated with the elimination of the Company’s dual class share structure; the attractiveness of the Company’s shares as acquisition currency following the Transaction; the price and liquidity of the Canopy Growth common shares; the Company’s intention to invest, acquire and/or merge with operating U.S. cannabis companies and the value to be derived therefrom; the Company’s belief that operating businesses in the U.S. cannabis market experience uncertain and constrained access to capital; the possibility that the Company may de-list from the TSX following completion of the Transaction and list its securities on a stock exchange that permits investments in and/or acquisitions of U.S. cannabis companies; the anticipated timing of the Meeting and the requisite shareholder approvals to be obtained at the Meeting; the Company obtaining and/or satisfying customary approvals and conditions, including court approval for the Transaction; and expectations for other economic, business, and/or competitive factors.

Investors are cautioned that forward-looking information is not based on historical fact but instead reflects management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. Financial outlooks, as with forward-looking information generally, are, without limitation, based on the assumptions and subject to various risks as set out herein.

Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: the parties’ ability to consummate the Transaction; the ability to receive, in a timely manner and on satisfactory terms, all necessary regulatory, court, shareholder, and other third party approvals; the ability of the parties to satisfy, in a timely manner, all other conditions to the closing of the Transaction; the potential impact of the announcement or consummation of the Transaction on relationships, including with regulatory bodies, stock exchanges, lenders, employees and competitors; the diversion of management time on the Transaction; assumptions concerning the Transaction and the operations and capital expenditure plans of the Company following completion of the Transaction; credit, liquidity and additional financing risks for the Company and its investees; stock market volatility; regulatory and licensing risks; changes in cannabis industry growth and trends; changes in the business activities, focus and plans of the Company and its investees and the timing associated therewith; the Company’s actual financial results and ability to manage its cash resources; changes in general economic, business and political conditions, including challenging global financial conditions and the impact of the novel coronavirus pandemic; competition risks; potential conflicts of interest; the regulatory landscape and enforcement related to cannabis, including political risks and risks relating to regulatory change; changes in applicable laws; changes in the global sentiment towards, and public opinion of, the cannabis industry; divestiture risks; competition risks; and the risk factors set out in the Circular and Canopy Rivers’ annual information form dated June 2, 2020 , filed with the Canadian securities regulators and available on Canopy Rivers’ profile on SEDAR at www.sedar.com .

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors that could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

$SRAX Announces Blockchain and Digital Media Expert Lou Kerner as CEO of BIGtoken

$POAI Announced Definitive Agreements for $2.2 Million Registered Direct Offering

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has entered into definitive agreements for the issuance and sale of more than 2 million shares of its common stock. The company announced that it has finalized definitive agreements with a number of institutional and accredited investors for the issuance and sale of approximately 2,200,000 common stock shares at $1.00 per share; the registered direct offering, priced at-the-market following Nasdaq rules, will result in gross proceeds of $2.2 million for the company. Predictive Oncology plans to use the net proceeds from the offering for working capital purposes. In addition, POAI agreed to issue unregistered warrants to the investors to purchase up to 1,100,000 additional shares of common stock. The company noted that the warrants have an exercise price equal to $1.00 per share and are exercisable upon issuance with an expiration date five and one-half years from the issuance date. POAI’s offering is expected to close on or about Jan. 21, 2021, pending customary closing conditions.

To view the full press release, visit: https://ibn.fm/acc6f

About Predictive Oncology Inc.

Predictive Oncology operates through three segments (domestic, international and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Soluble Biotech.  Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes. For more information about the company, please visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

$NETE Colorado Springs Gears Up for Surge in EVs

$CLXPF How the Psychedelics Industry Differs from the Cannabis Industry

$CRTD Releases Updates to Vocal Platform Designed to Enhance User Engagement, Support Subscription Growth

Creatd (NASDAQ: CRTD), a proprietary technology platform for creators of all types, announced the release of the first of a series of updates to its Vocal platform technology. The enhanced design and functionality updates are focused on increasing creator discoverability and enriching the user experience. The company noted that the platform updates should also drive continuing growth in conversions from freemium creators to premium Vocal+ subscribers. The initial update was unveiled last week and features a more intuitive user experience for Vocal’s creators and audiences as well as new community-specific metrics that highlight the health, safety and user volume of both the creators and platform communities. The Vocal platform currently has more than 850,000 creators on the freemium tier, with approximately  1,200 new freemium creators joining every day. In December 2020, Vocal+ reached 10,000 paid subscribers, a 117% increase since the start of that quarter. “These updates, the first of many on our 2021 product roadmap, are focused on improving the way we champion and curate quality stories from Vocal’s creator community, said Creatd founder, president and head of product Justin Maury in the press release. “They also lay the foundation for exponential conversion growth across the platform.”

To view the full press release, visit https://ibn.fm/JJ0sG

About Creatd Inc.

Creatd empowers creators, brands and entrepreneurs through technology and partnership. Its flagship technology, Vocal, is a best-in-class creator platform. For more information about the company, please visit www.Creatd.com.

NOTE TO INVESTORS: The latest news and updates relating to CRTD are available in the company’s newsroom at http://ibn.fm/CRTD

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

$BHAT Inks Multi-Year Licensing Agreement to Use WUHUANGWANSHUI Intellectual Property

Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT), a leading producer, developer and operator of augmented reality (“AR”) interactive entertainment games, toys and educational materials in China, today announced that it has signed a three-year licensing agreement with Cup of Cosmo Studio (Beijing) Culture Co., Ltd. The agreement enables BHAT to use Cup of Cosmo Studio’s WUHUANGWANSHUI intellectual property (“IP”) on social media, toys and marketing materials, effective January 1, 2021. WUHUANGWANSHUI is an original Chinese cartoon and consisting of an image brand set of a cat (Wu Huang) and a dog (Ba Zahey). The brand is easily recognized in Chinese pop culture. “We are pleased to be partnering with Cup of Cosmo Studio with this licensing agreement for their famed WUHUANGWANSHUI brand, which we are confident will increase Blue Hat’s exposure and attract the attention of more potential customers. We expect this collaboration to serve as a catalyst for our business development efforts and strengthen our brand recognition,” Blue Hat CEO Xiaodong Chen stated in the news release.

To view the full press release, visit https://ibn.fm/FnHKu

About Blue Hat

Blue Hat Interactive Entertainment Technology is a producer, developer and operator of AR interactive entertainment games and toys in China, including interactive educational materials, mobile games and toys with mobile-game features. The company’s entertainment platform creates unique user experiences by connecting physical items to mobile devices, which creates a rich visual and interactive environment for users through the integration of real objects and virtual scenery. Distinguished by its own proprietary technology, Blue Hat aims to create an engaging, interactive and immersive community for its users. For more information, please visit the company’s investor relations website at www.IR.BlueHatGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to BHAT are available in the company’s newsroom at http://ibn.fm/BHAT

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

$RACMF Integrates Major Cryptocurrency Payments into Contactless Payment Platform

Loop Insights (TSX.V: MTRX) (OTCQB: RACMF), a provider of contactless solutions and artificial intelligence (“AI”) to drive real-time insights, enhanced customer engagement, and automated venue tracing to the brick-and-mortar space has combined its patent-pending tech with major cryptocurrency payments to reach a significant milestone. The company announced that it had integrated Bitcoin, Ethereum and Litecoin into its contactless payments platform for use by retail customers and enterprise partners. The timing of this accomplishment is ideal as cryptocurrency payments are seeing a major paradigm shift toward global acceptance. The announcement marks the completion of the initial integration, which began in 2018; patents were filed in 2019, and the company has waited for moment when global commerce and regulatory acceptance of cryptocurrency payments created the greatest opportunity for success. “Whereas many companies try to use cryptocurrencies as a buzz word, Loop has been way ahead of this global paradigm shift to the delight of our customers and partners who want be ahead of what we anticipate being a parabolic growth decade for cryptocurrency transactions and payments,” said Loop Insights CEO Rob Anson in the press release. “Our Fobi device is already configured to accept leading cryptocurrencies including Bitcoin, Ethereum, and Litecoin, providing retailers with new long-term opportunities for growth and Enterprise partners with an even stronger value proposition that already includes our world-leading artificial intelligence-driven, real-time transaction technology.”

To view the full press release, visit http://ccw.fm/HqCN3

About Loop Insights Inc.

Loop Insights is a Vancouver-based Internet of Things (“IoT”) technology company that delivers transformative artificial intelligence (“AI”) automated marketing, contact tracing and contactless solutions to the brick-and-mortar space. Its unique IoT device, Fobi, enables data connectivity across online and on-premise platforms to provide real-time, detailed insights and automated, personalized engagement. RACMF’s ability to integrate seamlessly into existing infrastructure and customize campaigns according to each vertical creates a highly scalable solution for its prospective global clients that span industries. Loop Insights operates in the telecom, casino gaming, sports and entertainment, hospitality and retail industries in Canada, the United States, the UK, Latin America, Australia, Japan and Indonesia. Loop’s products and services are backed by Amazon’s Partner Network and sold through the TELUS IoT Marketplace. For more information about the company, please visit www.LoopInsights.ai.

NOTE TO INVESTORS: The latest news and updates relating to RACMF are available in the company’s newsroom at http://ibn.fm/RACMF

About CryptoCurrencyWire (“CCW”)

CryptoCurrencyWire (CCW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with CCW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, CCW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CCW brings its clients unparalleled visibility, recognition and brand awareness.

To receive instant SMS alerts, text CRYPTO to 77948 (U.S. Mobile Phones Only)

CryptoCurrency News Wire is where News, content and information converge via Crypto.

For more information, please visit https://www.CryptoCurrencyWire.com

Please see full terms of use and disclaimers on the CryptoCurrencyWire (CCW) website applicable to all content provided by CCW, wherever published or re-published: http://CCW.fm/Disclaimer

CryptoCurrencyWire (CCW)
New York, New York
www.CryptoCurrencyWire.com
212.994.9818 Office
Editor@CryptoCurrencyWire.com

CryptoCurrencyWire is part of the InvestorBrandNetwork.

$POAI Subsidiary Sells Media to Top Research Medical Centers

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has announced that TumorGenesis, POAI’s wholly owned subsidiary, sold media to top research medical centers in New York City and Boston. The announcement noted that those two sales are repeat orders and focus on culturing ovarian cancer cells with specific research goals; the company also announced an additional order that came from a private company conducting research on ovarian cancer. Experts forecast that the 3D cancer cell culture media market will grow at CAGR of approximately 11.3%, reaching $3.2 billion in sales in worldwide by 2027. According to the announcement, the reason for the significant growth is because older technologies do not generally reproduce a patient’s tumor cell populations, and immortalized cells, or cells that live forever and are altered from the original tumor, do not make good models for use in drug discovery and development. The company called the idea of replicating ovarian cancer cells outside of a patient’s body and in a laboratory well plate or culture flask remarkable. “We believe that this is the future of ovarian cancer research, which creates new possibilities to coming up with new treatments for this chronic and deadly disease,” said POAI president and CEO Dr. Carl Schwartz in the press release. “In order for us to find better drugs, we have to be able to grow the right patient cells in the right media. Building the ‘living library’ of cancer cells for drug screening and discovery is the right first step. Then we can focus on how to kill them.”

To view the full press release, visit https://ibn.fm/8LIzH

About Predictive Oncology Inc.

Predictive Oncology operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement, and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins, and protein complexes. For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

$ICLK 52-Week High Recently Eclipsed

Shares of iClick Interactive Asia Group Limited (NASDAQ:ICLK) traded today at $12.00, eclipsing its 52-week high. Approximately 253,000 shares have changed hands today, as compared to an average 30-day volume of 1 million shares.

iClick Interactive Asia Group Ltd is an independent online marketing and enterprise data solutions provider in China. It serves as an integrated cross-channel gateway that provides marketers with innovative and cost-effective ways to optimize their online marketing efforts throughout their marketing cycle and achieve their branding and performance-based marketing goals. It has two operating segments: Marketing Solutions, and Enterprise Solutions. Geographically, it derives majority revenue from PRC and also has a presence in Hong Kong and other countries.

iClick Interactive Asia Group Limited share prices have moved between a 52-week high of $12.00 and a 52-week low of $3.01 and are now trading 286% above that low price at $11.61 per share.

iClick Interactive Asia Group Limited (NASDAQ:ICLK) defies analysts with a current price ($11.61) 30.7% above its average consensus price target of $8.04.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

$GNPX Slated to Present at NobleCon17

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has announced that it will present at the upcoming NobleCon17, scheduled for Jan. 19–20, 2021. The virtual event is Noble Capital Markets’ annual investor conference. GNPX’s presentation will include a company overview and address the company’s recent progress on planned clinical trials focusing on the treatment of non-small cell lung cancer. Genprex president and CEO Rodney Varner will deliver the presentation to participating investors. The Genprex presentation is scheduled for Tuesday, Jan. 19, at 3:45 p.m. EST.  A replay of the presentation will be available on the company’s website and in a catalog of all NobleCon17 presentations to be rebroadcast on Channelchek.

To register for the event, visit https://ibn.fm/C5HbI

To view the full press release, visit https://ibn.fm/01koH

About Genprex Inc.

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company’s lead product candidate, REQORSA(TM) (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso(R)) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone. For more information, visit the company’s website at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

$UUUU to Present at NobleCon17 on Tuesday, January 19, 2021

LAKEWOOD, Colo. , Jan. 14, 2021 – Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) (“Energy Fuels” or the “Company”) , a leading producer of uranium and critical minerals in the United States , is pleased to announce that the Company’s President and CEO Mark S. Chalmers will present at NobleCon17 – Noble Capital Markets’ Seventeenth Annual Investor Conference on Tuesday, January 19, 2021 at 10:30 AM (EST) . The conference is virtual, with no cost, obligation or restrictions to attend: www.nobleconference.com .

Mr. Chalmers will provide an update on Energy Fuels’ various uranium and critical mineral initiatives, with particular emphasis on the Company’s progress on producing rare earth elements.

A high-definition, video webcast of the presentation will be available the following day on the Company’s website at www.energyfuels.com , and as a part of a complete catalog of presentations to be rebroadcast on Channelcheck ( www.channelchek.com ) next month.

About Energy Fuels: Energy Fuels is a leading U.S.-based uranium mining company, supplying U ₃ O ₈ to major nuclear utilities. The Company also produces vanadium from certain of its projects, as market conditions warrant, and anticipates commencing commercial production of rare earth element (“REE”) carbonate in 2021. Its corporate offices are in Lakewood, Colorado , near Denver , and all of its assets and employees are in the United States . Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah , the Nichols Ranch in-situ recovery (“ISR”) Project in Wyoming , and the Alta Mesa ISR Project in Texas . The White Mesa Mill is the only conventional uranium mill operating in the U.S. today, has a licensed capacity of over 8 million pounds of U ₃ O ₈ per year, has the ability to produce vanadium when market conditions warrant, and is completing final test-work for the production of REE carbonate from various uranium-bearing ores. The Nichols Ranch ISR Project is on standby and has a licensed capacity of 2 million pounds of U ₃ O ₈ per year. The Alta Mesa ISR Project is also on standby and has a licensed capacity of 1.5 million pounds of U ₃ O ₈ per year. In addition to the above production facilities, Energy Fuels also has one of the largest NI 43-101 compliant uranium resource portfolios in the U.S. and several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. The primary trading market for Energy Fuels’ common shares is the NYSE American under the trading symbol “UUUU,” and the Company’s common shares are also listed on the Toronto Stock Exchange under the trading symbol “EFR.” Energy Fuels’ website is www.energyfuels.com .

About Noble Capital Markets : Noble Capital Markets (“Noble”) is a research driven boutique investment bank that has supported small & micro-cap companies since 1984. As a FINRA and SEC licensed and registered broker-dealer, Noble provides institutional-quality equity research, merchant and investment banking, wealth management and order execution services. In 2005, Noble established NobleCon, an investor conference that has grown substantially over the last decade+. In 2018, Noble launched www.channelchek.com – an investment community dedicated exclusively to small and micro-cap companies and their industries. Channelcheck is tailored to meet the needs of self-directed investors and financial professionals and is the first service to offer institutional-quality research to the public, for FREE at every level without a subscription. More than 6,000 emerging growth companies are listed in the site, with growing content including webcasts, industry sector reports, advanced market data and balanced news.

Cautionary Note Regarding Forward-Looking Statements: This news release contains certain “Forward-Looking Information” and “Forward-Looking Statements” within the meaning of applicable United States and Canadian securities legislation, which may include, but are not limited to, statements with respect to any expectations regarding: the Company being a leading producer of uranium and critical minerals in the United States ; various uranium and critical mineral initiatives of the Company; and the Company’s progress on producing rare earth elements . Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as “plans,” “expects,” “does not expect,” “is expected,” “is likely,” “budgets,” “scheduled,” “estimates,” “forecasts,” “intends,” “anticipates,” “does not anticipate,” or “believes,” or variations of such words and phrases, or state that certain actions, events or results “may,” “could,” “would,” “might” or “will be taken,” “occur,” “be achieved” or “have the potential to.” All statements herein, other than statements of historical fact, are considered to be forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance of or achievements of the Company to be materially different from any future results, performance, or achievements, express or implied, by the forward-looking statements. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements include risks associated with: the Company being a leading producer of uranium and critical minerals in the United States ; various uranium and critical mineral initiatives of the Company; the Company’s progress on producing rare earth elements ; and the other factors described under the caption “Risk Factors” in the Company’s most recently filed Annual Report on Form 10-K, which is available for review on EDGAR at www.sec.gov/edgar.shtml , on SEDAR at www.sedar.com , and on the Company’s website at www.energyfuels.com . Forward-looking statements contained herein are made as of the date of this news release, and the Company disclaims, other than as required by law, any obligation to update any forward-looking statements whether as a result of new information, results, future events, circumstances, or as a result of changes in management’s estimates or opinions, or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements. The Company assumes no obligation to update the information in this communication, except as otherwise required by law.

$RACMF Enters Strategic Agreement with Leading UK Pharmacy Solutions Provider

Loop Insights (TSXV: MTRX) (OTCQB: RACMF), a provider of contactless solutions and artificial intelligence (“AI”) to drive real-time insights, enhanced customer engagement and automated venue tracing to the brick-and-mortar space, today announced the signing of a pilot agreement with PharmAssist Solutions to implement Loop’s analytics platform into multiple independent pharmacy affiliated locations. “Loop Insights data analytics solution is a game-changer for independent pharmacies here in the UK. PharmAssist Solutions has been integral to the success of the independent chain, and adding Loop’s ability to understand transaction details, shopping behaviors and habits, trends, and other powerful pieces of information once thought lost, will provide a massive benefit to each individual pharmacy,” Pharmassist Managing Director Amar Randhawa stated. “Understanding what products have been sold and prescribed gives these independents the ability to offer personal, relevant, and adjacent over the counter products to consumers, increasing sales, and delivering a more personal experience in-store. We are excited to be the first solutions provider in the UK market to offer this, and expect great uptake of the solution to our growing customer base.”

To view the full press release, visit http://ibn.fm/BF223

About Loop Insights Inc.

Loop Insights is a Vancouver-based Internet of Things (“IoT”) technology company that delivers transformative artificial intelligence (“AI”) automated marketing, contact tracing and contactless solutions to the brick-and-mortar space. Its unique IoT device, Fobi, enables data connectivity across online and on-premise platforms to provide real-time, detailed insights and automated, personalized engagement. Its ability to integrate seamlessly into existing infrastructure, and customize campaigns according to each vertical, creates a highly scalable solution for its prospective global clients that span industries. Loop Insights operates in the telecom, casino gaming, sports and entertainment, hospitality, and retail industries, in Canada, the US, the UK, Latin America, Australia, Japan, and Indonesia. Loop’s products and services are backed by Amazon’s Partner Network and sold through the TELUS IoT Marketplace. For more information, visit the company’s website at www.LoopInsights.ai.

NOTE TO INVESTORS: The latest news and updates relating to RACMF are available in the company’s newsroom at http://ibn.fm/RACMF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

$RACMF Announces Film Bubble Partnership, New CFO Appointment

$POAI Secures $3.074M in Registered Direct Offering

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the closing of its previously disclosed registered direct offering of 3,650,840 shares of its common stock, at a purchase price of $0.842 per share, priced at-the-market under Nasdaq rules. Predictive Oncology secured $3.074 million in gross proceeds from the offering. In a concurrent private placement, Predictive Oncology also issued to the same investors unregistered warrants to purchase up to an aggregate of 1,825,420 shares of common stock at an exercise price of $0.80 per share. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

To view the full press release, visit http://ibn.fm/IV2JI

About Predictive Oncology Inc.

Predictive Oncology operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement, and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins, and protein complexes. For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

$CNSP CEO Appears on C3 Chat Show Podcast

CNS Pharmaceuticals (NASDAQ: CNSP) chairman and CEO John Climaco was featured on a recent C3 Chat Show Podcast. The podcast, hosted by Sid Vaidya and Eric Gershey, explores topics related to entrepreneurship, life experiences and best practices. During his interview, Climaco shared the history of CNS Pharmaceuticals and provided an update on the company’s recent business progress, including the fact that the company recently received FDA approval to begin clinical trials studying the company’s lead drug candidate, Berubicin. CNSP is developing Berubicin as a potential treatment for glioblastoma multiforme (“GBM”), an aggressive form of brain cancer currently considered incurable. Climaco called Berubicin a “powerhouse compound” and said the FDA approval was a big day for GBM patients, which is a population that has seen little innovation for the past 15 years. “This is the biggest news we’ve announced since our IPO back in November 2019,” Climaco said in the press release. “The FDA approved an Investigational New Drug application, which allows us to proceed with our clinical trial. Based on that IND approval, we expect, in the next 90 to 120 days, we will go from zero active clinical trials today to three active clinical trials for our lead compound, Berubicin, which is a novel treatment for glioblastoma, the most common and aggressive form of primary brain cancer. . . . If you get GBM, the sad reality is you’re probably going to die from it. We think we can change that game.”

To hear the full podcast, visit http://ibn.fm/IDQi3

To view the full press release, visit http://ibn.fm/ZdFo5

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of February 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. By the end of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the United States, while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. The company’s second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation. For more information about the company, please visit www.CNSPharma.com

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at http://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

$CNSP Moving Forward with New Berubicin Clinical Trials, Determined to Help Address Unmet Needs of GBM Patients

$SRAX Announces Extension of BIGtoken Special Dividend

$SRAX Slated to Host, Present at B. Riley Securities 2021 Vision Day

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies, will be both hosting and presenting at the upcoming B. Riley Securities 2021 Vision Day via its Sequire Virtual Events platform. SRAX, which unlocks data and insights for publicly traded companies through Sequire, its SaaS platform, has been selected as one of B. Riley’s top picks for 2021. The most recent addition to Sequire’s suite of products, the Virtual Events platform provides a way for companies to virtually present to institutional and retail investors. The B. Riley Securities 2021 Vision Day is an invitation-only virtual event for a select group of U.S. institutional investors and senior management from B. Riley’s analysts’ 2021 Vision picks. The event includes brief company presentations along with fireside chats hosted by B. Riley Securities analysts. B. Riley Securities is a leading full-service investment bank and subsidiary of B. Riley Financial that provides corporate finance, advisory, research, sales and trading services to corporate, institutional and high-net-worth clients.  “We recognize that virtual events are here to stay, and for public companies, the platform offers everything issuers need to host their meetings with maximum exposure,” said SRAX founder and CEO Christopher Miglino in the press release.

To view the full press release, visit http://ibn.fm/xZYqf

About SRAX

SRAX is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information about the company, please visit www.SRAX.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

$DRIO Appoints Diabetes, Behavioral Health Experts to Scientific Advisory Board

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, announced the appointment of two renowned experts to its Scientific Advisory Board (“SAB”). Dr. Marilyn Ritholz, psychologist at Joslin Diabetes Center, a Harvard Medical School affiliate, and Dr. David Horwitz, former global chief medical officer of Johnson & Johnson Diabetes Institute, join SAB chairman Eric Milledge; the prestigious board is focused on advancing Dario’s technical leadership, helping to guide the development of the company’s bold technology road map and advancing Dario’s DTx (“DTx”) platform by integrating members’ comprehensive experience and expertise into the company offering. Ritholz and Horwitz are recognized as experts in the fields of diabetes, metabolism, and behavioral health. A senior psychologist at the Joslin Diabetes Center, Ritholz is also on the faculty at Beth Israel Deaconess Medical Center (“BIDMC”) and is an assistant professor of psychology at Harvard Medical School. A senior consultant with Numerof & Associates, Horwitz also serves as president of DLH Biomedical Consulting and has previously held faculty positions in the medical schools at the University of Chicago and the University of Illinois. “My objective is to populate Dario’s SAB with renowned members of the global medical community who align with Dario’s approach to empower individuals to achieve meaningful, sustainable behavior change through highly personalized, AI-driven experiences that adapt dynamically through a member’s journey,” said Milledge in the press release. “Dr. Ritholz’s accomplishments at the Joslin Diabetes Center, a Harvard Medical School affiliate, include a leading practice focused on the intersection of psychology and diabetes management in adolescents and adults. Her expertise will be key in refining aspects of our technology for improved patient-provider interactions and, ultimately, better care. Dr. Horwitz’s experiences as a Board-Certified internist and endocrinologist, coupled with his knowledge of the healthcare ecosystem, will lay the foundation for a strong board committed to improving patient care. I am excited to work with them as we continue to build out the SAB and drive continued innovation of Dario’s platform.”

To view the full press release, visit http://ibn.fm/0jsJu

About DarioHealth Corp.

DarioHealth Corp. is a leading global digital therapeutics company revolutionizing how people with chronic conditions manage their health. By delivering evidence-based interventions driven by connected devices, data, high-quality software and coaching, the company makes the right thing to do the easy thing to do. The company’s cross-functional team operates at the intersection of life sciences, behavioral science and software technology. Dario offers one of the highest-rated diabetes and hypertension solutions on the market. The highly engaging, user-centric MyDario(TM) mobile app is used regularly by tens of thousands of consumers worldwide. The company is rapidly expanding into new chronic conditions and geographic markets, using a performance-based approach to improve its users’ health. For more information about the company, please visit www.DarioHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

$WTER to Launch Alkaline88(R) Products at 99 Cents Only Stores

The Alkaline Water Company (CSE: WTER) (NASDAQ: WTER), a producer of premium bottled alkaline and flavored-infused drinking waters and CBD-infused products, today announced that its three-liter offering and four A88-Infused(TM) flavored waters will be available in all 99 Cents Only Stores locations across California and the Southwest regions. “We are pleased to announce that our flagship brand and four of our popular flavors will be offered by another exciting banner in the specialty discount retail channel,” stated Ricky Wright, president and CEO of The Alkaline Water Company. “As a trusted national brand, it is encouraging to see our brand extension strategy in play, with our new and innovative offerings creating larger opportunities for our team. During calendar 2020, our efforts to penetrate this space have yielded strong results. Our small and large formats are now carried in approximately 8,000 stores in this channel, with a strong sales pipeline for the current year. The specialty discount channel presents a tremendous opportunity for our growing lifestyle brands, and we expect to add another 6,000 to 8,000 new store locations over the next 12-18 months. Our earlier wins in this channel are seeing good momentum with consistent repeat orders and strong turns. Beyond our beverage brands, we believe that our A88CBD products will do exceptionally well in this channel, especially as the CBD regulatory framework is further defined in 2021.”

To view the full press release, visit http://cnw.fm/xKUy0

About The Alkaline Water Company

Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88 delivers perfect 8.8 pH-balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked label: Clean Beverage. Quickly being recognized as a growing lifestyle brand, Alkaline88 launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused flavored water is available in six unique all-natural flavors with new flavors coming soon. Additionally, in 2020, the company launched A88 Infused Beverage Division Inc., which includes the company’s CBD water and flavor-infused water. For the company’s topical and ingestible offerings, A88 Infused Products includes both the company’s lab-tested, full-spectrum hemp salves, balms, lotions, essential oils and bath salts, along with broad-spectrum hemp, powder packs, oil tinctures, capsules and gummies. To learn more about the company, visit www.A88CBD.com and www.TheAlkalineWaterCo.com.

NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://cnw.fm/WTER

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

$CLXPF Research Shows Ketamine Helps Major Depressive Disorder Patients Adjust How They Perceive Reality

$SGLB Secures $5.1M in Underwritten Public Offering

Sigma Labs (NASDAQ: SGLB), a leading developer of quality assurance software for the commercial metal 3D printing industry, has announced the closing of its previously disclosed underwritten public offering of 1,488,507 shares of common stock, each at a public offering price of $3.00. In connection with the offering, the underwriter exercised in full its over-allotment option to purchase an additional 223,276 shares of common stock at the public offering price, less the underwriting discount. Sigma Labs secured $5,135,349 in gross proceeds from the offering consisting of 1,711,783 shares. H.C. Wainwright & Co. acted as the sole book-running manager for the offering.

To view the full press release, visit http://ibn.fm/hdyDq

About Sigma Labs Inc.

Sigma Labs is a leading provider of in-process quality assurance (IPQA(R)) software to the additive manufacturing industry. Sigma specializes in the development and commercialization of real-time monitoring solutions known as PrintRite3D(R) for 3D metal advanced manufacturing technologies. PrintRite3D detects and classifies defects and anomalies real-time during the manufacturing process, enabling significant cost-savings and production efficiencies. Sigma Labs believes its software product will be a major catalyst for the acceleration and adoption of 3D metal printing. For more information, please visit www.SigmaLabsInc.com.

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

$GNPX Passes Final Release Tests for Manufacturing Run of Proprietary Immunogene Therapy Treatment

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, announced that it has achieved a significant milestone for its REQORSA(TM) Immunogene Therapy. The company has met all specifications and passed all final release tests for its initial scaled-up, clinical-grade manufacturing run of REQORSA(TM) immunogene therapy. This achievement comes in advance of GNPX’s upcoming Acclaim-1 and Acclaim-2 clinical trials for the treatment of non-small cell lung cancer (“NSCLC”). This announcement also follows the company’s successful completion of the technology transfer of the manufacturing process for the production of REQORSA from the major research institution where it was previously manufactured to experienced commercial contract development and manufacturing organizations (“CDMOs”). In addition, Genprex noted that it has also completed the manufacturing scale-up for the clinical-grade production of REQORSA, subject to final testing that is already underway. According to the company, clinical-grade REQORSA has been shipped and delivered to a cold storage depot, the first step to the product being delivered to the clinical trial sites; the company is now waiting for FDA clearance to start those trials. “The successful completion of this final step in our scaled-up clinical grade manufacturing of REQORSA marks a key manufacturing milestone for Genprex, and is credited to the hard work and commitment of both our internal manufacturing group and our manufacturing partners,” said Genprex president and CEO Rodney Varner in the press release. “This production provides supply of REQORSA for our two upcoming Acclaim clinical trials and advances our mission to develop innovative new treatments for non-small cell lung cancer patients greatly in need of effective therapy options.”

To view the full press release, visit: https://ibn.fm/k1jIF

About Genprex Inc.

Genprex is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to in-license and develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company’s lead product candidate, GPX-001 (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). GPX-001 has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. GPX-001 has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted fast track designation for GPX-001 for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso(R)) for patients with EFGR (“EFGR”) mutations whose tumors progressed after treatment with osimertinib alone. For more information, please visit the company’s website at www.Genprex.com

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

$UUUU CEO Featured in Exclusive NetworkNewsAudio Interview

Energy Fuels (NYSE American: UUUU) (TSX: EFR) president and CEO Mark Chalmers was featured during a recent NetworkNewsAudio segment. During the interview, the president of the country’s largest producer of uranium and the leading conventional producer of vanadium discussed the company’s newly released sustainability report and its entry into rare earths production. Chalmers noted that the company is starting the new year preparing to enter a new business: the commercial production of rare earth elements (“REE”); the company’s portfolio also includes a pipeline of high-quality, large-scale exploration and development projects. “We are first and foremost a uranium producer, the largest producer of uranium in the United States,” said Chalmers during the interview. “We also announced in April we’re entering the rare earth sector. We just recently announced that we secured a supply agreement with The Chemours Company for the purchase of monazite ore, which contains both uranium and rare earths. In addition, we’ve got substantial traction with the U.S. government on supporting a national uranium reserve, which our company had a lot to do with in D.C. So it’s been a busy year, despite the COVID issues. . . . When you look at all the positive impacts we have as a company when it comes to reducing carbon emissions, whether it be the uranium production for providing nuclear power, the recycling we’ve done for the past couple of decades, the vanadium sector where we have the only primary vanadium plant in the U.S., or our entrance into rare earths, we cover all these critical minerals and materials that are focused on reducing carbon emissions in a more energy-efficient society.”

To listen to the full interview, visit https://ibn.fm/tMI7p

To view the full press release, visit https://ibn.fm/Di6ax

About Energy Fuels Inc.

Energy Fuels is a leading U.S.-based uranium mining company, supplying U3O8 (“U308”) to major nuclear utilities. The company also produces vanadium from certain of its projects, as market conditions warrant, and anticipates commencing commercial production of rare earth element (“REE”) carbonate in 2021. Its corporate offices are in Lakewood, Colorado, near Denver, and all of its assets and employees are in the United States. Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR”) Project in Wyoming, and the Alta Mesa ISR Project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the United States today, has a licensed capacity of over 8 million pounds of U3O8 per year, has the ability to produce vanadium when market conditions warrant, and is completing final test-work for the production of REE carbonate from various uranium-bearing ores. The Nichols Ranch ISR Project is on standby and has a licensed capacity of 2 million pounds of U3O8 per year. The Alta Mesa ISR Project is also on standby and has a licensed capacity of 1.5 million pounds of U3O8 per year. In addition to the above production facilities, Energy Fuels also has one of the largest NI 43-101 compliant uranium resource portfolios in the U.S. along with several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. For more information, visit the company’s website at www.EnergyFuels.com. 

NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

About MiningNewsWire

MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.

To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.MiningNewsWire.com

Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer

MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com

MiningNewsWire is part of the InvestorBrandNetwork.

$CRTD 52-Week High Recently Eclipsed

Creatd Inc. (NASDAQ:CRTD) traded at a new 52-week high today of $4.50. Approximately 183,000 shares have changed hands today, as compared to an average 30-day volume of 78,000 shares.

Creatd, Inc. (Nasdaq CM: CRTD) empowers creators, brands, and entrepreneurs through technology and partnership. Its flagship technology platform is Vocal; Vocal provides creators of all shapes and sizes, from bloggers to podcasters, and more, with best-in-class storytelling tools, safe and curated communities, and the opportunity to monetize their content. With 34 owned and operated communities, Vocal enables creators to connect to their ideal audiences and to partner with the brands that want to reach those audiences.

Creatd Inc. share prices have moved between a 52-week high of $4.50 and a 52-week low of $2.10 and are now trading 115% above that low price at $4.50 per share.

Creatd Inc. (NASDAQ:CRTD) defies analysts with a current price ($4.50) 60.3% above its average consensus price target of $1.79.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

$ICLK Issues Shareholder Letter, Corporate Update

iClick Interactive Asia Group (NASDAQ: ICLK), an independent online marketing and enterprise data solutions provider in China, today announced the release a letter to shareholders from its CEO Jian “T.J.” Tang. In the letter, Tang reported success on three targeted milestones, the first of which outlined the company’s improved profitability for its marketing solutions. The update reads, “iClick has realized an adjusted net profit for four quarters in a row due primarily to the business having realized economies of scale and as a result of our efforts with new marketing formats, such as multi-channel networks (‘MCN’), key opinion leaders (‘KOL’) and short-form videos. Notably, iFans, our KOL marketing intelligence platform, has been selected as SaaS Premium Select as part of Tencent’s Qianfan Plan and will help brands and MCNs realize marketing digitalization by leveraging Tencent Cloud. Based on our current outlook, we are optimistic that 2020 will be our first full year of positive adjusted net income.”

To view the full press release, visit https://ibn.fm/0l1Tq

About iClick Interactive Asia Group Limited.

iClick Interactive Asia Group is an independent online marketing and enterprise data solutions provider that connects worldwide marketers with audiences in China. Built on cutting-edge technologies, iClick’s proprietary platform possesses omni-channel marketing capabilities and fulfils various marketing objectives in a data-driven and automated manner, helping both international and domestic marketers reach their target audiences in China. Headquartered in Hong Kong, iClick was established in 2009 and is currently operating in ten locations worldwide, including Asia and Europe. For more information about the company, please visit ir.i-Click.com.

NOTE TO INVESTORS: The latest news and updates relating to ICLK are available in the company’s newsroom at http://ibn.fm/ICLK

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.